Specialty pharmacy expands access to an innovative, steroid-free treatment NEW PROVIDENCE, NJ, UNITED STATES, March 3, 2025 /EINPresswire / -- ...

The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...

Copyright: © 2025 The Author(s). Published by Elsevier Ltd.

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporte ...

I don't recall the exact date when I realized my chronic, widespread pain wasn't normal. But the summer of 2019 stands out. I woke up one morning after a solo drive from Seattle to Orange County ...

St. Vincent’s Riverside is now offering a breakthrough treatment for patients diagnosed with chronic pulmonary obstructive disease (COPD)/emphysema.>>> STREAM ACTION NEWS JAX LIVE [DOWNLOAD: Free ...

CBD is one of several cannabinoids naturally present in the cannabis plant. A vast range of CBD products, including oils, tinctures, and balms, may help people experiencing physical pain. This ...

Current guidelines recommend use of one or more long-acting inhaled bronchodilators for patients with moderate, severe, or very severe COPD. However, the initial choice of long-acting inhaled ...

Ohtuvayre™ is the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Verona has evaluated ...